Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward

While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.